Amyl Therapeutics
Signal active
Organization
Contact Information
Overview
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
About
Industries
Biotechnology, Life Science, Health Care, Medical
Founded
2020
Employees
1-10
Headquarters locations
Europe
Social
N/A
Profile Resume
Amyl Therapeutics headquartered in Europe, operates in the Biotechnology, Life Science, Health Care, Medical sector. The company focuses on Biotechnology and has secured $2.2B in funding across 64 round(s). With a team of 1-10 employees, Amyl Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Amyl Therapeutics, raised $5.7M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
3
Lead Investors
0
Total Funding Amount
$34.4M
Details
2
Amyl Therapeutics has raised a total of $34.4M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Early Stage Venture | 10.4M | ||
| 2023 | Early Stage Venture | 5.7M |
Investors
Amyl Therapeutics is funded by 21 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Gaëtan Servais | - | FUNDING ROUND - Gaëtan Servais | 5.7M |
| Amel Tounsi | - | FUNDING ROUND - Amel Tounsi | 5.7M |
| Amyl Therapeutics | - | FUNDING ROUND - Amyl Therapeutics | 5.7M |
| Meusinvest (Noshaq) | - | FUNDING ROUND - Meusinvest (Noshaq) | 5.7M |
Recent Activity
There is no recent news or activity for this profile.